Abstract
Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest growing cause of cancer deaths among Americans. Guidelines recommend biannual ultrasound-based screening, with or without a serum biomarker alpha fetoprotein (AFP) for early detection of HCC in at-risk individuals with cirrhosis. Our objective was to estimate the overall cost of HCC screening from a commercial healthcare system’s perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
